Skip to main content

Tianeptine for Treatment Resistant Depression

Sponsored by

This event is over.

Event Details:

The Stanford Depression Research Clinic is seeking people with major depressive disorder (MDD) to participate in a new research study evaluating the effectiveness of a medication called tianeptine for people whose symptoms have not responded to standard antidepressants. Although not approved by the FDA to treat depression in the United States, Tianeptine is an atypical antidepressant that has been used clinically in Europe, Asia, and South America since the late 1980s in millions of patients. Tianeptine is a different type of antidepressant than those currently approved in the United States in that it has a different mechanism of action than other antidepressants.

You may be eligible if you are between the ages of 21 and 60, currently depressed, and have a history of trying at least two antidepressant medications. After screening, eligible participants will receive an 8-week treatment trial of tianeptine. The study requires at least 9 visits to our research clinic over approximately two months. Participants will receive compensation for their time.

Learn more about our current research and to complete the online screening form visit our website or email Maureen Chang -

For complaints, concerns, or participant's rights, contact 1-866-680-2906.